



1- μ mol synthesis of RNA using ÄKTA oligopilot plus 10

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company. Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.
For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

1- μ mol synthesis of RNA using ÄKTA oligopilot plus 10

The pilot scale synthesis instruments from GE Healthcare, ÄKTA™ oligopilot™ 10 and ÄKTA oligopilot 100 have been upgraded in regards to hardware, software, and synthesis methods. As a result of the upgrade, ÄKTA oligopilot plus 10 has become a highly efficient system for 1- μ mol scale synthesis of RNA oligonucleotides

Synthesis

RNA oligonucleotides of various lengths were synthesised using an ÄKTA oligopilot plus 10 system. The methods for 1- μ mol scale synthesis of phosphodiester RNA oligonucleotides

have been optimized and, relative to the original version of ÄKTA oligopilot 10 system, significant improvements have been made in terms of reagent consumption, quality of the oligonucleotides synthesized, and cycle time. The reagents used for synthesis and deprotection are listed in Table 1 below. Synthesis of oligonucleotides in the 1- μ mol scale was carried out in disposable cassettes. Empty cassettes and appropriate filters are available from GE Healthcare (code number 18-1035-19). Best results have been obtained with cassettes packed with Custom Primer Support™ 40s, 25 mg/cassette. Prior to start of synthesis, the cassettes were placed in

Table 1. Reagents used for synthesis, cleavage and deprotection

Reagent	Composition/quality	Supplier	Code number
Solid support, 1 g	Custom Primer Support ribo A 40s,	GE Healthcare	17-5225-17
Solid support, 1 g	Custom Primer Support ribo C 40s,	GE Healthcare	17-5225-18
Solid support, 1 g	Custom Primer Support ribo G 40s,	GE Healthcare	17-5225-19
Solid support, 1 g	Custom Primer Support ribo U 40s,	GE Healthcare	17-5225-20
Amidite rA ^{bz} , 1 g	TheraPure® phosphoroamidite, 2'TBDMS	Pierce Milwaukee	27-1903-02
Amidite rC ^{ac} , 1 g	TheraPure® phosphoroamidite, 2'TBDMS	Pierce Milwaukee	27-1805-02
Amidite rG ^{iso} , 1 g	TheraPure® phosphoroamidite, 2'TBDMS	Pierce Milwaukee	27-1906-02
Amidite rU, 1 g	TheraPure® phosphoroamidite, 2'TBDMS	Pierce Milwaukee	27-1904-02
Acetonitrile, 2.5 L	DNA synthesis grade	EMD Chemicals	AXO152/2505
Detritylation, 1 L	3% DCA in toluene	EMD Chemicals	BIO832/1005
Activator, 1 L	BTT (benzylthiotetrazole) 0.3 M, in ACN	EMD Chemicals	BIO166/1005
Capping A, 0.5 L	20% NMI in ACN	EMD Chemicals	BIO224/0505
Capping B, 2x0.2 L	20% Ac ₂ O, 30% 2,6-lutidine in ACN	EMD Chemicals	BIO347/0200 BIO349/0200
Oxidation, 1 L	50 mM I ₂ in pyridine/water 9:1	EMD Chemicals	BIO424/1005
Deprotection, 0.5 L	20% diethylamine in ACN	EMD Chemicals	NC0017-0505
Cleavage & deprotection, 2 L	33% Methylamine in ethanol/conc ammonium hydroxide 1:1		
Desilylation	Triethylamine 3HF Dimethylsulfoxide		
Precipitation	n-butanol		



column holders (code number 18-1142-91) connected to ÄKTA oligopilot plus 10. The reagent consumption for the optimized synthesis cycle for 1 μmol synthesis is shown in Table 2.

Table 2. Reagent consumption for 1 μmol synthesis on ÄKTA oligopilot plus 10

Reagent	Amount
Acetonitrile	18.5 ml
Detritylation	5 ml
Amidite	20 eq, 17 mg
Activator	0.3 ml
Oxidation	0.2 ml
Capping A	0.3 ml
Capping B	0.3 ml

The time for completion of one synthesis cycle is approximately 16 min. This means that a 20-mer can be synthesized in just above 5 h.

Cleavage and base deprotection

After synthesis, the solid support (still in the cassette) was transferred to a microcentrifuge tube with the flange up. The tube was placed in a small table centrifuge and spun for about 1 min at medium speed (2000 rpm) to remove the acetonitrile inside the cassette. The cassette was then transferred to a screw-cap microcentrifuge tube. A 1ml mixture of 33% methylamine in ethanol and ammonium hydroxide 1:1 was added and the solution allowed to enter the cassette by centrifuging for about 1 min at medium speed. The tube containing the cassette was then heated in an oven at 60°C to 65°C for 2 h and then allowed to cool to room temperature. The cassette was then transferred to a new microcentrifuge tube and the cleavage solution still inside the cassette was collected at the bottom of the tube after centrifugation for about 1 min at medium speed. The cassette was then removed from the tube and the cleavage solution was combined with the solution in the original tube. The cleavage solution was evaporated to dryness in a speedvac.

Desilylation

The crude RNA oligonucleotide, still carrying the 2'-TBDMS groups was dissolved in 0.1 ml of DMSO. 1 ml of Triethylamine3HF (TREAT) was added, the tube was capped, and the mixture was shaken vigorously to ensure complete dissolution. The bottle was heated in an oven at 60°C to 65°C for 3 to 3.5 h. The tube was removed from the oven and cooled to room temperature.

Precipitation

The solution containing the completely desilylated oligonucleotide was cooled on ice. 40 μl 5M NaClO_4 and 1.3 ml -20°C acetone was carefully added to precipitate the oligonucleotide. The precipitate was vortexed and incubated in a freezer for 30 minutes. The pellet was spun down and washed once with -20°C 100% acetone, followed by wash once with 80% EtOH and then dried.

Yield determination

After cleavage and deprotection, the synthesis yields were determined by measuring the absorbance at 260 nm of an aliquot of the crude mixture diluted in water. In order to make the yields comparable for different synthesis scales, they are expressed as A_{260} units/ μmol .

HPLC purity analysis

After cleavage and deprotection, the purity of the crude reaction mixtures were analyzed by ion exchange (IEX) HPLC using the conditions shown in Table 3.

Table 3. Conditions used for IEX HPLC analysis

HPLC system	Agilent 1100
Column	DNA Pac™ PA100
Injection volume	2 μl
Sample concentration	20 to 30 A_{260} units/ml
Buffer A	1 mM Tris, 10 mM NaClO_4
Buffer B	1 mM Tris, 300 mM NaClO_4
Flow rate	1000 $\mu\text{l}/\text{min}$
Gradient	1% to 55% B in 30 min
Column temperature	50°C

Results

With the procedures described above, very high synthesis efficiency is obtained. Average coupling efficiency is in the 98.5% to 99% range. Examples of HPLC analyses of crude material after synthesis and deprotection are shown below for a 21-mer (Fig 1).

21-mer phosphodiester

Yield: 122 OD/ μ mol
Purity: 71%
N-1: 3%




Fig 1. HPLC analysis of 21-mer phosphodiester.

Conclusions

The use of optimized synthesis methods for 1- μ mol scale synthesis of RNA oligonucleotides in ÄKTA oligopilot plus 10 in combination with the use of Custom Primer Support 40s gives oligonucleotides of very high yield and purity.

Related literature

Application Note optimization and scale-up of siRNA synthesis Code No 28-4057-96.

For contact information for your local office,
please visit, www.gelifesciences.com/contact

www.gelifesciences.com/oligo

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden



GE, imagination at work, and GE monogram are trademarks of General Electric Company.

ÅKTA, OligoPilot and Primer Support are trademarks of GE Healthcare companies.

DNA Pac is a trademark of Dionex Corporation. Therapure is a trademark of Pierce Milwaukee LLC.

The use of ÅKTA oligopilot and OligoProcess instruments is licensed under US Patent Nos. 4,458,066 and 4,973,679, and corresponding patents issued in other countries, when synthesis of polynucleotides is performed thereon using solid phase supports provided from a licensed supplier. Patented reagents suitable for use with these instruments are available from licensed sources. No other license is granted to the purchaser either directly or by implication, estoppel or otherwise.

© 2006-2007 General Electric Company – All rights reserved.

First published April 2006.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information

GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Bio-Sciences KK, Sanken Bldg., 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo, 169-0073 Japan